Dosing Protocol
Typical Dose 15 mg
Range 10 - 20 mg
Maintenance 15 mg daily
Pharmacokinetics
Half-Life 4.1 hrs
Onset 30 min
Peak 1.5 hrs
Duration 6.0 hrs
Bioavailability 30%
Primary Route Oral
Administration
Routes Oral
Syringe Type Oral
Timing Fasted, Before Bed
Special Instructions
Development discontinued by Novo Nordisk due to CYP3A4 inhibition. Research compound only. Significant drug interaction potential.